Navigation Links
DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
Date:1/26/2009

t of Orthopaedics and Rehabilitation at the Yale University School of Medicine in New Haven, Connecticut. "Moreover, as of October 2008, the Centers for Medicare and Medicaid (CMS) are no longer paying for hospital-acquired infections; therefore, healthcare facilities are going to have to absorb these staggering costs."

"DiFUSION's solution addresses the U.S. Department of Health and Human Services' (HHS) action plan released January 2009 to reduce and eliminate healthcare-associated infections (HAIs), one of the key areas being surgical site infections," said Dr. Matthew Geck, founder and board member of DiFUSION and leading orthopaedic surgeon in Austin, Texas. "Our technology can have a profound impact on lowering the devastating infection rates recently reported by the HHS' Centers for Disease Control and Prevention (CDC). HAIS are among the top ten leading causes of death in the United States, accounting for an estimated 1.7 million infections and 99,000 associated deaths in 2002."

The infection-fighting material used in DiFUSION's CleanFUZE(TM) is a 'super silicate' molecule composed of antimicrobial silver ions that is compounded into the plastic spinal interbody cage. Once the CleanFUZE(TM) interbody cage is implanted into the spinal disc space during spinal surgery, silver ions exchange with naturally occurring sodium ions in the bloodstream and diffuse antimicrobial silver ions for a period of 4 weeks.

Unlike other devices on the market, DiFUSION's CleanFUZE(TM) will be capable of releasing its dosage amount over time and the rate of diffusion can be controlled by parts-per-billion. Additionally, rather than antimicrobial coatings currently used in devices, CleanFUZE(TM) contains antimicrobial properties embedded in the device, significantly enhancing the effectiveness.

"Larger companies have spent years and millions of dollars trying to address the SSI problem with antimic
'/>"/>

SOURCE DiFUSION Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
9. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
10. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
11. DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... Dec. 9 BioMarin Pharmaceutical,Inc. (Nasdaq: ... partner Merck Serono, a division,of Merck KGaA, ... (sapropterin dihydrochloride) for the treatment of,hyperphenylalaninemia (HPA) ... the European Commission. Merck Serono estimates ...
... DCTH ) today announced the appointment of Roger G. ... Executive Chairman of Cortex Pharmaceuticals, Inc. (Amex: COR ), ... disorders. , , (Logo: ... Prior to joining Cortex, Dr. Stoll worked as a consultant ...
... Md., Dec. 9 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases, today,announced ... of ENMD-2076 in refractory,multiple myeloma patients. The study ... Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. ...
Cached Biology Technology:Kuvan Receives Marketing Approval in the European Union 2Kuvan Receives Marketing Approval in the European Union 3Kuvan Receives Marketing Approval in the European Union 4Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 3EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 2EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 3EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 4
(Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
(Date:8/20/2014)... Health has awarded the Oklahoma Medical Research Foundation a ... anthrax and the bacteria,s effects on humans. , ... his colleagues have studied the human immune response to ... Human Immunology. The original funding came soon after anthrax-laced ... of the terrorist attacks of Sept. 11, 2001. ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2$14.5 million grant awarded to continue anthrax studies 2
... Rome, Italy: Researchers have developed a way of accurately ... blood test. The average difference between the predicted age and ... the menopause was only a third of a year, and ... years. Dr Fahimeh Ramezani Tehrani will tell the 26th ...
... new technology that allows scientists to monitor how individual cells ... researchers have uncovered a much larger spectrum of differences between ... act in a uniform fashion, as was previously thought. ... Markus Covert, PhD, assistant professor of bioengineering and senior author ...
... 27th, 2010 The Elsevier Foundation, TWAS and TWOWS ... scientists from Africa, the Middle East, Asia, Latin America ... was made at the Third World Organization for Women ... Women Scientists in a Changing World, hosted by the ...
Cached Biology News:Researchers develop accurate way to predict the age when women will hit the menopause 2Researchers develop accurate way to predict the age when women will hit the menopause 3Same types of cell respond differently to stimulus, Stanford study shows 2Same types of cell respond differently to stimulus, Stanford study shows 312 women scientists announced as winners of Elsevier Foundation TWOWS Awards 2
... Ambion's custom siRNA service provides the premium ... silencing research. Custom siRNAs can be readily ... base target sequence, or by providing the ... out Ambion's Silencer Validated and Silencer Pre-designed ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Biology Products: